Radiotracer imaging of dopaminergic transmission in neuropsychiatric disorders

Psychopharmacology

Volumn 147, Issue 3, 1999, Pages 217-249

  Verhoeff, Nicolaas Paul L G ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Dopamine; PET; Receptor; SPECT; Transporter

Indexed keywords

AMINO ACID DECARBOXYLASE; AMPHETAMINE; BUTYROPHENONE; COCAINE; HALOPERIDOL; OLANZAPINE; RACLOPRIDE; RISPERIDONE; SPIPERONE; TYROSINE 3 MONOOXYGENASE;

ADULT; CASE REPORT; DEPRESSION; DOPAMINERGIC TRANSMISSION; DRUG BINDING SITE; GILLES DE LA TOURETTE SYNDROME; HUMAN; HUMAN CELL; HUMAN TISSUE; HUNTINGTON CHOREA; MALE; NEUROLEPTIC MALIGNANT SYNDROME; NEUROPSYCHIATRY; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOCIAL PHOBIA; WILSON DISEASE;

DOPAMINE; HUMANS; MENTAL DISORDERS; NERVOUS SYSTEM DISEASES; RECEPTORS, DOPAMINE; SYNAPTIC TRANSMISSION; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0033986964     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130051163     Document Type: Review

References (370)

1. Abi-Dargham A, Gandelman MS, DeErasquin GA, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Laruelle M, Charney DS, Hoffer PB, Neumeyer JL, Innis RB (1996) SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of β-CIT. J Nucl Med 37:1129-1133
2. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M (1998) Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155:761-767
3. 2 receptor binding potential associated with social phobia. J Nucl Med 40:144P
4. 11C]NNC 756. Synapse 32:93-109
5. 2 receptors in schizophrenia. J Nucl Med 40:30P
6. 2 dopamine and muscarinic cholinergic receptor densities in caudate specimens from fluctuating parkinsonian patients. Ann Neurol 30:185-191
7. Ahonen A, Laine TPJ, Niemala O, Räsänen P, Torniainen P, Heikkilä J, Pyhtinen J, Hiltunen J, Hillbom M (1996) Striatal dopamine and serotonin transporter levels in alcoholics during ethanol withdrawal. Eur J Nucl Med 23:1088
8. 2 receptor immunoreactivity to synapses formed by tyrosine hydroxylase-positive terminals in the monkey striatum. Soc Neurosci Abstr 24:857
9. 2 dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men. Psychopharmacology 131:339-345
10. 11C]-raclopride. Ann NY Acad Sci 695:81-85
11. 2-receptors. Neurology 44:1325-1329
12. 2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease. Brain 119:2085-2095
13. 11C]raclopride. Mov Disord 12:33-38
14. Antonini A, Leenders KL, Vontobel P, Maguire RP, Missimer J, Psylla M, Gunther I (1997b) Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 120:2187-2195
15. 11C]raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length. Ann Neurol 43:253-255
16. Arnold G, Tatsch K, Oertel WH, Vogl T, Schwarz J, Kraft E, Kirsch CM (1994) Clinical progressive supranuclear palsy: differential diagnosis by IBZM-SPECT and MRI. J Neural Transm Suppl 42:111-118
17. 123I][β-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm 105:1213-1228
18. B receptor in gamma vinyl-GABA's inhibition of cocaine-induced increases in nucleus accumbens dopamine. Synapse 31:151-153
19. Assies J, Verhoeff NPLG, Bosch DA, Hofland LJ (1993) Intracranial dissemination of a macroprolactinoma. Clin Endocrinol 38:539-546
20. Backman L, Robins-Wahlin TG, Lundin A, Ginovart N, Farde L (1997) Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. Brain 120:2207-2217
21. 123I]N-Ω-fluoroalkyl-2β-carboxy-3β-(4-iodophanyl)nortropane esters in baboons. Nucl Med Biol 22:211-219
22. 76Br]bromospiperone binding sites demonstrated by positron tomography in progressive supranuclear palsy. J Cereb Blood Flow Metab 6:131-136
23. 2 receptors by the neuroleptic ziprasidone (CP-88, 059-01) determined by positron emission tomography. Psychopharmacology 124:141-147
24. 123I]β-CIT in human plasma may obstruct quantification of the dopamine transporter. Synapse 19:297-300
25. 2 receptors in vivo in rat brain. Implications for PET studies. J Recept Signal Transduct Res 17:419-431
26. 2 receptors in tardive dyskinesia: PET study. J Neurol Neurosurg Psychiatr 52:1248-1252
27. 11C]Dihydrotetrabenazine PET imaging in familial paroxysmal dystonic choreoathetosis. Neurology 52:1067-1069
28. Booij J (1998) Imaging of dopamine transporters in Parkinson's disease with single photon emission computed tomography. Thesis, University of Amsterdam, The Netherlands, pp 171-185
29. 123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease. Eur J Nucl Med 24:68-71
30. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 62:133-140
31. Booij J, Habraken JBA, Bergmans P, Tissingh G, Winogrodzka A, Wolters ECh, Janssen AGM, Stoof KC, van Royen EA (1998) Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med 39:1879-1884
32. 123I]IPT single photon emission computed tomography. J Neurol Neurosurg Psychiatry 65:263-265
33. Bowers MB Jr, Malison RT, Seibyl JP, Kosten TR (1998) Plasma homovanillic acid and the dopamine transporter during cocaine withdrawal. Biol Psychiatry 43:278-281
34. 11C]SDZ GLC 756. Synapse 30:341-350
35. Brashaer A, Mulholland GK, Zheng QH, Farlow MR, Siemers ER, Hutchins GD (1999) PET imaging of the pre-synaptic dopamine uptake sites in rapid-onset dystonia-parkinsonism (RDP). Mov Disord 14:132-137
36. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94:2569-2574
37. 2 receptor density and personal detachment in healthy subjects. Am J Psychiatry 155:1440-1442
38. Breier A, Adler CM, Weisenfeld N, Su TP, Elman I, Picken L, Malhotra AK, Pickar D (1998b) Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse 29:142-147
39. Breier A, Su TP, Malhotra AK, Elman I, Adler CM, Weisenfeld NI, Pickar D (1999) Effects of atypical antipsychotic drug treatment on amphetamine-induced striatal dopamine release in patients with psychotic disorders. Neuropsychopharmacology 20:340-345
40. Brooks DJ (1993) Functional imaging in relation to parkinsonian syndromes. J Neurol Sci 115:1-17
41. 18F-dopa uptake in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Ann Neurol 28:547-555
42. 11C-raclopride and positron emission tomography. Ann Neurol 31:184-192
43. Brownell AL, Hantraye P, Wullner U, Hamberg L, Soup T, Elmaleh DR, Frim DM, Madras BK, Brownell GL, Rosen BR et al. (1994) PET- and MRI-based assessment of glucose utilization, dopamine receptor binding, and hemodynamic changes after lesions to the caudate-putamen in primates. Exp Neurol 125:41-51
44. Brownell AL, Livni E, Galpern W, Isacson O (1998) In vivo PET imaging in rat of dopamine terminals reveals functional neural transplants. Ann Neurol 43:387-390
45. 2 receptor imaging and measurement with SPECT. Adv Neurol 60:494-500
46. 123I]β-CIT. Binding kinetics in human brain. J Neural Transm [Gen Sect] 94:137-146
47. 2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. A SPECT study. J Cereb Blood Flow Metab 15:513-518
48. 123I] β-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 50:9-24
49. Buck A, Westera G, Sutter M, Albani C, Kung HF, Von Schultess GK (1995) Iodine-123-IBF SPECT evaluation of extrapyramidal diseases. J Nucl Med 36:1196-1200
50. Burchett SA, Volk ML, Bannon MJ, Granneman JG (1998) Regulators of G protein signaling: rapid changes in mRNA abundance in response to amphetamine. J Neurochem 70:2216-2219
51. 123I-IBZM single photon emission tomography (SPET) study. Psychopharmacology 117:55-61
52. Bylund DB, Yamamura HI (1990) Methods for receptor binding. In: Yamamura HI, Enna SJ, Kuhar MJ (eds) Methods in neurotransmitter receptor analysis. Raven Press, New York, pp 1-35
53. Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20:140-144
54. Carpenter WT, Buchanan RW, Karno M, Norquist GS (1995) Schizophrenia. In: Kaplan HI, Sadock BJ (eds) Comprehensive textbook of psychiatry/VI, 6th edn. Williams and Wilkins, Baltimore, pp 889-1018
55. Cepeda C, Levine MS (1998) Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum. Dev Neurosci 20:1-18
56. 2 receptor with iodine-iodolisuride: results in supranuclear palsy. J Nucl Med 33:1481-1485
57. 1 selective benzonaphthazepine with potential antipsychotic activity. J Pharmacol Exp Ther 247:1093-1102
58. 2 receptor SPECT imaging in Rett syndrome: increase of specific binding in striatum. J Nucl Med 34:1717-1721
59. Chiueh CC (1988) Dopamine in the extrapyramidal motor function. A study based upon the MPTP-induced primate model of parkinsonism. In: Joseph JA (ed) Central determinants of aged-related declines in motor function (Ann NY Acad Sci, vol 515). The New York Academy of Sciences, New York, pp 226-238
60. 2 receptors. Ann Neurol 34:219-226
61. Dao-Castellana MH, Paillere-Martinot ML, Hantraye P et al. (1997) Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr Res 23:167-174
62. 2 receptor radioligand. Clin Endocrinol 45:755-767
63. De Keyser J, Ebinger G, Vauquelin G (1990) Age-related changes in the human nigrostriatal dopaminergic system. Ann Neurol 27:157-161
64. Demeter S (1992) Structural imaging in Tourette syndrome. Adv Neurol 58:201-206
65. 18F)-N-methylspiroperidol binding in the baboon brain using positron emission tomography (PET). Synapse 7:324-327
66. 11C-raclopride and positron emission tomography. J Neurosci 12:3773-3780
67. 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 13:350-356
68. Dewey SL, Smith GS, Logan J, Brodie JD, Simkowitz P, MacGregor RR, Fowler JS, Volkow ND, Wolf AP (1993b) Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects. Proc Natl Acad Sci USA 90:11816-11820
69. Dewey SL, Smith GS, Logan J, Alexoff D, Ding YS, King P, Pappas N, Brodie JD, Ashby CR Jr (1995) Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci 15:821-829
70. Dewey SL, Morgan AE, Ashby CR Jr, Horan B, Kushner SA, Logan J, Volkow ND, Fowler JS, Gardner EL, Brodie JD (1998) A novel strategy for the treatment of cocaine addiction. Synapse 30:119-129
71. Dewey SL, Brodie JD, Gerasimov M, Horan B, Gardner EL, Ashby CR Jr (1999) A pharmacologic strategy for the treatment of nicotine addiction. Synapse 31:76-86
72. 2 receptors in depression measured with single photon emission computed tomography. Biol Psychiatry 35:128-132
73. Donnemiller E, Ransmayr G, Heilmann J, Berger W, Poewe W, Riccabona G (1996) Distinction between dementia of Alzheimer type (DAT) and of diffuse Lewy-body disease (DLBD). Eur J Nucl Med 23:1078
74. 2 receptor occupancy in risperidone-treated schizophrenic patients. J Nucl Med 39:1138-1142
75. Dresel SH, Kung MP, Huang XF, Plossl K, Hou C, Meegalla SK, Patselas G, Mu M, Saffer JR, Kung HF (1999) Simultaneous SPECT studies of pre- and postsynaptic dopamine binding sites in baboons. J Nucl Med 40:660-666
76. Drukarch B (1991) Biochemical aspects of signal transduction via D-2 dopamine receptors in the rat central nervous system. Thesis, Free University, Amsterdam, The Netherlands
77. 1 dopamine receptor in striatal neurons in vivo as evidence of activation by dopamine agonists. J Neurosci 18:1650-1661
78. 4 receptor clones depends on the radioligand used. Soc Neurosci Abstr 21:617
79. Ebert D, Berger M (1998) Neurobiological similarities in anti-depressant sleep deprivation and psychostimulant use: a psychostimulant theory of antidepressant sleep deprivation. Psychopharmacology 140:1-10
80. 2 receptor blockade in depression before and after sleep deprivation - preliminary results. Biol Psychiatry 35:880-885
81. 2 receptor SPECT before and after antidepressant therapy. Psychopharmacology 126:91-94
82. Edelstein H, Knight RT (1987) Severe parkinsonism in two AIDS patients taking prochlorperazine. Lancet 2:341-342
83. Ekesbo A, Rydin E, Torstenson R, Sydow O, Längstrom B, Tedroff J (1999) Dopamine autoreceptor function is lost in advanced Parkinson's disease. Neurology 52:120-125
84. 2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45:71-76
85. 2 dopamine receptors in neuroleptic-naive schizophrenic patients. Arch Gen Psychiatry 47:213-219
86. 2-receptor occupancy in clozapine-treated patients. J Clin Psychiatry 55:67-69
87. 11C[raclopride in man. Synapse 20:200-208
88. 2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol 15:19S-23S
89. 2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients. Psychopharmacology 133:396-404
90. 2 occupancy, extrapyramidal side effects and antipsychotic drug treatment: a pilot study with sertindole in healthy subjects. Int Clin Psychopharmacol 12:S3-S7
91. Fernell E, Watanabe Y, Adolffson I, Tani Y, Bergstrom M, Hartvig P, Lilja A, von Knorring AL, Gillberg C, Langstrom B (1997) Possible effects of tetrahydrobiopterin treatment in six children with autism - clinical and positron emission tomography data: a pilot study. Dev Med Child Neurol 39:313-318
92. Fischman AJ, Bonab AA, Babich JW, Palmer EP, Alpert NM, Elmaleh DR, Callahan RJ, Barrow SA, Graham W, Meltzer PC, Hanson RN, Madras BK (1998) Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse 29:128-141
93. Fletcher PC, Frith CD, Grasby PM, Friston KJ, Dolan RJ (1996) Local and distributed effects of apomorphine on fronto-temporal function in acute unmedicated schizophrenia. J Neurosci 16:7055-7062
94. Freed CR, Breeze RE, Rosenberg NL et al. (1992) Survival of implanted fetal dopamine cells and neurologic improvement 12 to 16 months after transplantation for Parkinson's disease. N Engl J Med 327:1549-1555
95. 2 receptor SPECT analysis. Eur Neurol 35:50-54
96. 2 receptors. Synapse (in press)
97. 11C]cocaine binding to decreases in synaptic dopamine. Synapse 20:137-144
98. 11C]methylphenidate to the dopamine transporter in vivo: insensitivity to synaptic dopamine. Eur J Pharmacol 281:141-149
99. 2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology 135:119-126
100. George MS, Robertson MM, Costa DC, Ell PJ, Trimble MR, Pilowsky L, Verhoeff NP (1994) Dopamine receptor availability in Tourette's syndrome. Psychiatry Res 55:193-203
101. Gerasimov MR, Ashby CR Jr, Gardner EL, Mills MJ, Brodie JD, Dewey SL (1999) Gammavinyl GABA inhibits methamphetamine, heroin, or ethanol-induced increases in nucleus accumbens dopamine. Synapse 34:11-19
102. 11C]dihydrotetrabenazine and positron emission tomography. Ann Neurol 44:326-333
103. Ginovart N, Lundin A, Farde L, Halldin C, Backman L, Swahn CG, Pauli S, Sedvall G (1997) PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain 120:503-514
104. 2-receptor density following chronic treatment with amphetamine as assessed with PET in nonhuman primates. Synapse 31:154-162
105. 2 dopamine receptors in the temporal lobe in schizophrenia. Arch Gen Psychiatry 54:649-658
106. Grace AA (1991) Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41:1-24
107. 1 receptor supersensitivity. II. Inilateral intra-carotid infusion of MPTP in the monkey (Macaca fascicularis). Brain Res 514:103-110
108. Groenewegen HJ, Berendse HW, Meredith GE et al. (1991) Functional anatomy of the ventral, limbic system-innervated striatum. In: Willner P, Scheel-Krüger J (eds) The mesolimbic dopamine system: from motivation to action. Wiley, London, pp 19-58
109. Groenewegen HJ, Roeling TAP, Voorn P, Berendse HW (1993) The parallel arrangement of basal ganglia-thalamocortical circuits: A neuronal substrate for the role of dopamine in motor and cognitive functions. In: Wolters ECh, Scheltens P (eds) Mental dysfunction in Parkinson's disease. Free University, Amsterdam, The Netherlands, pp 3-18
110. Haber SN, Kowell NW, Vonsattel JP, Bird ED, Richardson EP (1986) Gilles de la Tourette's syndrome: a postmortem neuropathological and histochemical study. J Neurol Sci 75:225-241
111. 2 receptor occupancy by an atypical neuroleptic. Psychiatry Res 82:147-160
112. 2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology 11:245-256
113. 125I]NCQ 298 binding to human brain extrastriated dopamine receptors. Nucl Med Biol 24:389-393
114. 1-dopamine receptors. J Nucl Med 39:2061-2068
115. 2 receptor blockade after depot neuroleptics. J Neural Transm [Gen Sect] 94:217-221
116. Hartvig P, Torstenson R, Tedroff J, Watanabe Y, Fasth KJ, Bjurling P, Langstrom B (1997) Amphetamine effects on dopamine release and synthesis rate studied in the rhesus monkey brain by positron emission tomography. J Neural Transm 104:329-339
117. Hauser RA, Zesiewicz TA. Management of early Parkinson's disease (1999) Med Clin N Am 83:393-414
118. Heinz A, Jones DW, Gorey JG, Knable MB, Lee KS, Saunders RC, Weinberger DR (1997) Analysis of the metabolites of [I-123] β-CIT in plasma of human and nonhuman primates. Synapse 25:306-308
119. Heinz A, Knable MB, Coppola R, Gorey JG, Jones DW, Lee KS, Weinberger DR (1998a) Psychomotor slowing, negative symptoms and dopamine receptor availability - an IBZM SPECT study in neuroleptic-treated and drug-free schizophrenic patients. Schizophr Res 31:19-26
120. Heinz A, Knable MR, Wolf SS, Jones DW, Gorey JG, Hyde TM, Weinberger DR (1998b) Tourette's syndrome [I-123]β-CIT SPECT correlates of vocal severity. Neurology 51:1069-1074
121. Heinz A, Saunders RC, Kolachana BS, Jones DW, Gorey JG, Bachevalier J, Weinberger DR (1999) Striatal dopamine receptors and transporters in monkeys with neonatal temporal limbic damage. Synapse 32:71-79
122. 2 receptor imaging with iodine-123-iodobenzamide SPECT in idiopathic rotational torticollis. J Nucl Med 35:1921-1927
123. 2 receptor binding sites in parkinsonian plus syndromes. J Nucl Med 39:954-960
124. 2 dopamine receptor binding characteristics in vivo in patients with alcohol dependence. Psychopharmacology 116:285-290
125. Hietala J, Syvalahti E, Vuorio K, Rakkolainen V, Bergman J, Haaparanta M et al. (1995) Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 346:1130-1131
126. Hietala J, Syvalahti E, Vilkman H et al. (1999) Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr Res 35:41-50
127. 3H]GBR-12935 binding sites in human striatal membranes: binding characteristics and changes in parkinsonians and schizophrenics. Jpn J Pharmacol 47:237-243
128. 123I-IBZM. Acta Neurol Scand 90:186-189
129. 2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease. J Nucl Med 34:1274-1281
130. 2 receptor binding with iodine-123-iodobenzofuran SPECT. J Nucl Med 39:1511-1518
131. Ichise M, Kim YJ, Ballinger JR, Vines D, Erami SS, Tanaka F, Lang AE (1999) SPECT imaging of pre- and postsynaptic dopaminergic alterations in L-dopa-untreated PD. Neurology 52:1206-1214
132. Ilgin N, Zubieta J, Reich SG, Dannals RF, Ravert HT, Frost JJ (1999) PET imaging of the dopamine transporter in progressive supranuclear palsy and Parkinson's disease. Neurology 52:1221-1226
133. Innis RB (1994) SPECT imaging of dopamine terminal innervation: potential clinical tool in Parkinson's disease. Eur J Nucl Med 21:1-5
134. 2 receptor in nonhuman primates. Synapse 10:177-184
135. Innis RB, Seibyl JP, Scanley BE, Laruelle M, Abi-Dargham A, Wallace E, Baldwin RM, Zea-Ponce Y, Zoghbi S, Wang S, Gao Y, Neumeyer JL, Charney DS, Hoffer PB, Marek KL (1993) Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in parkinson disease. Proc Natl Acad Sci USA 90:11965-11969
136. Innis RB, Malison RT (1995) Principles of neuroimaging. In: Kaplan HI, Sadock BJ (eds) Comprehensive textbook of psychiatry/VI, 6th edn. Williams and Wilkins, Baltimore, pp 89-103
137. 123I[β-CIT. Mov Disord: 14:436-442
138. Ishikawa T, Dhawan V, Kazumata K, Chaly T, Mandel F, Neumeyer J, Margouleff C, Babchyck B, Zanzi I, Eidelberg D (1996) Comparative nigrostriatal dopaminergic imaging with iodine-123-β CIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med 37:1760-1765
139. 2 receptors in susceptibility to methamphetamine psychosis detected by positron emission tomography. Psychiatry Res 50:217-231
140. Jankovic J (1987) The neurology of tics. In: Marsden CD, Fahn S (eds) Movement disorders 2. Butterworths, London, pp 383-405
141. 123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome. Mov Disord 11:726-728
142. 123I]-β-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease. J Neurol Neurosurg Psychiatry 65:60-64
143. 123I]β-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia. Ann Neurol 43:792-800
144. 2 receptor imaging with iodine-123-iodobenzamide brain SPECT in infants with hypoxic-ischemic brain injury. J Nucl Med 39:1703-1707
145. Kapur S (1998) A new framework for investigating antipsychotic action in humans: lessons form PET imaging. Mol Psychiatry 3:135-140
146. 2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 57:PL103-107
147. 2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry 153:948-950
148. 2 receptors: implications for the therapeutics of schizophrenia. Am J Psychiatry 154:1525-1529
149. 2 receptor occupancy and plasma levels on low dose haloperidol: a PET study. Psychopharmacology 131:148-152
150. 2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 155:921-928
151. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156:286-293
152. 2 receptor occupancy in comparison to risperidone, clozapine and haloperidol. Psychopharmacology 136:367-373
153. Kaufman MJ, Madras BK (1991) Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's diseased striatum. Synapse 9:43-49
154. Kazumata K, Dhawan V, Chaly T, Antonini A, Margouleff C, Belakhlef A, Neumeyer J, Eidelberg D (1998) Dopamine transporter imaging with fluorine-18-FPCIT and PET. J Nucl Med 39:1521-1530
155. 123I]IBZM SPECT measurement of amphetamine-induced striatal dopamine release in humans. Synapse 31:302-308
156. 123I]IBZM SPECT. J Nucl Med 40:30P
157. 11C-raclopride. Neurology 44:2102-2104
158. Kish SJ, Shannak K, Hornykiewics O (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 318:876-880
159. Kish SJ, Robitaille Y, El-Awar M et al. (1991) Brain amino acid reductions in one family with chromosome 6p-linked dominantly inherited olivopontocerebellar atrophy. Ann Neurol 30:780-784
160. Kish SJ, Robitaille Y, El-Awar M et al. (1992) Striatal monoamine neurotransmitters and metabolites in dominantly inherited olivopontocerebellar atrophy. Neurology 42:1573-1577
161. 11C]-raclopride and positron-emission tomography. Neurology 50:1028-1032
162. Knable MB, Jones DW, Copola R, Hyde TM, Lee KS, Gorey J, Weinberger DR (1995) Lateralized differences in iodine-123-IBZM Uptake in the basal ganglia in asymmetric Parkinson's disease. J Nucl Med 36:1216-1225
163. Koepp MJ, Gunn RN, Lawrence AD, Cunningham VJ, Dagher A, Jones T, Brooks DJ, Bench CJ, Grasby PM (1998) Evidence for striatal dopamine release during a video game. Nature 393:266-268
164. Konradi C, Leveque JC, Hyman SE (1996) Amphetamine and dopamine-induced immediate early gene expression in striatal neurons depends on postsynaptic NMDA receptors and calcium. J Neurosci 16:4231-4239
165. Krieckhaus EE, Donahoe JW, Morgan MA (1992) Paranoid schizophrenia may be caused by dopamine hyperactivity of CA1 hippocampus. Biol Psychiatry 31:560-570
166. Kufferle B, Tauscher J, Asenbaum S, Vesely C, Podreka I, Brücke T (1997) IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol. Psychopharmacology 133:323-328
167. Kuhar MJ, Carroll I, Lewin AH, Boja JW, Scheffel U, Wong DF (1997) Imaging transporters for dopamine and other neurotransmitters in brain. In: Reith MEA (ed) Neurotransmitter transporters. Structure, function and regulation. Humana Press, Totowa, NJ, pp 297-313
168. Kuikka JT, Bergström KA, Ahonen A, Hiltunen J, Haukka J, Länsimies, Wang S, Neumeyer JL (1995) Comparison of iodine-123 labelled 2β-carbomethoxy-3β-(4-iodophenyl) tropane and 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)nortropane for imaging of the dopamine transporter in the living human brain. Eur J Nucl Med 22:356-360
169. Kung HF, Kim HJ, Kung MP, Meegalla S, Plössl K, Lee HK (1996) Imaging of dopamine transporter in humans with technetium-99m TRODAT-1. Eur J Nucl Med 23:1527-1530
170. 3H]-NGD-94-1. Schizophr Res 18:173
171. Laihinen AO, Rinne JO, Nagren KA, Lehikonen PK, Oikonen VJ, Ruotsalainen UH, Ruottinen HM, Rinne UK (1995) PET studies on brain monoamine transporters with carbon-11-β-CIT in Parkinson's disease. J Nucl Med 36:1263-1267
172. Laruelle M (1998) Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med 42:211-221
173. 123I]β-CIT: pharmacological characterisation of brain uptake in nonhuman primates. Synapse 13:295-309
174. 123I]β-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 14:982-994
175. Laruelle M, Abi-Dargham A, Gil R, Erdos J, D'Souza CD, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal J, Charney DS, Innis RB (1996a) SPECT measurement of dopamine transporters in schizophrenia. J Nucl Med 37:33P (Abstract)
176. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB (1996b) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drugfree schizophrenic subjects. Proc Natl Acad Sci USA 93:9235-9240
177. Laruelle M, Iyer R, Al-Tikriti M et al. (1997a) Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 25:1-14
178. 2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 17:162-174
179. 2 receptor gene. Mol Psychiatry 3:261-265
180. 2 dopamine receptors of patients with Parkinsons's disease using single photon emission computed tomography and iodobenzamide I 123. Arch Neurol 50:509-512
181. Lawrence AD, Weeks RA, Brooks DJ, Andrews TC, Watkins LH, Harding AE, Robbins TW, Sahakian BJ (1998) The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease. Brain 121:1343-1355
182. Leenders KL (1986) Movement disorders. A study with positron emission tomography. Thesis, Free University, Amsterdam, The Netherlands, pp 194-201
183. Leenders KL, Aquilonius SM, Bergström K (1988) Unilateral MPTP lesion in a rhesus monkey: effects on the striatal dopaminergic system measured in vivo with PET using various novel tracers. Brain Res 445:61-67
184. 2 receptor occupancy in human volunteers measured using positron emission tomography (PET). Eur J Clin Pharmacol 44:135-140
185. 11C]-N-methyl-spiperone binding in patients with focal dystonia (torticollis) using positron emission tomography. J Neural Transm Park Dis Dement Sect 5:79-87
186. Lesch KP, Bengel D, Heils A, Sabol, Greenberg BD, Petri S, Benjamin J, Müller CR, Hamer DH, Murphy DL (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274:1527-1531
187. 2 receptor imaging. J Nucl Med 37:1589-1591
188. 4 dopamine receptor mRNAs in the primate cerebral cortex versus neostriatum: effects of chronic treatment with typical and atypical antipsychotic drugs. J Pharmacol Exp Ther 283:939-946
189. 5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs. J Pharmacol Exp Ther 281:597-603
190. Lindstrom, L, Gefvert O, Lundberg T et al. (1998) Increased dopamine synthesis in prefrontal cortex and striatum in patients with schizophrenia studied with PET. CINPM meeting, July 12-17, Glasgow, UK
191. Lindvall O, Widner H, Rehncrona S et al. (1992) Transplantation of fetal dopamine neurons in Parkinson's disease - one year clinical and neurophysiological observations in two patients with putaminal implants. Ann Neurol 31:155-165
192. 2 receptor binding in sleep bruxism: a controlled study with iodine-123-iodobenzamide and single-photon-emission computed tomography. J Dent Res 75:1804-1810
193. 11C]cocaine and PET. Synapse 27:347-356
194. Lundberg C, Martinez-Serrano A, Cattaneo E, McKay RD, Bjorklund A (1997) Survival, integration, and differentiation of neural stem cell lines after transplantation to the adult rat striatum. Exp Neurol 145:342-360
195. Madras BK, Grasz LM, Fahey MA, Elmaleh D, Maltzer PC, Liang AY, Stopa EG, Babich J, Fischman AJ (1998) Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain. Synapse 29:116-127
196. 123I]β-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder. Am J Psychiatry 152:1359-1361
197. 123I]β-CIT SPECT measures of dopamine transporter availability in human cocaine addicts. Psychopharmacology 122:358-362
198. 123I]β-CIT SPECT imaging of dopamine transporter availability after mazindol administration in human cocaine addicts. Psychopharmacology 137:321-325
199. 123I]βCIT SPECT. Am J Psychiatry 155:832-834
200. 2 receptors: evidence for identical binding sites. Eur J Pharmacol 303:123-128
201. 123I]β-CIT SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 46:231-237
202. Marie RM, Barre L, Rioux P, Allain P, Lechevalier B, Baron JC (1995) PET imaging of neocortical monoaminergic terminals in Parkinson's disease. J Neural Transm Park Dis Dement Sect 9:55-71
203. Martinez-Serrano A, Bjorklund A (1996) Protection of the neostriatum against excitotoxic damage by neurotrophin-producing, genetically modified neural stem cells. J Neurosci 16:4604-4616
204. 2 receptors and negative symptoms of schizophrenia. Br J Psychiatry 164:27-34
205. 11C]WIN-35,428. J Neurosci 18:8417-8422
206. Meador-Woodruff JH, Damask SP, Wang J, Haroutunian V, Davis K, Watson SJ (1996) Dopamine receptors mRNA-expression in human striatum neocortex. Neuropsychopharmacology 15:17-29
207. 11C]WIN 35,428 - positron emisison tomography studies. Neurosci Lett 258:17-20
208. Meltzer PC, Blundell P, Jones AG, Mahmood A, Garada B, Zimmerman RE, Davison A, Holman BL, Madras BK (1997) A technetium-99 m SPECT imaging agent which targets the dopamine transporter in primate brain. J Med Chem 40:1835-1844
209. 18F]dopa striatal uptake: results of positron-emission tomography in Parkinson's disease. J Neuropsychiatr Clin Neurosci 7:176-179
210. Miller DW, Abercrombie ED (1996) Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats. Brain Res Bull 40:57-62
211. 2 receptor binding with age in rhesus monkeys: importance of correction for differences in striatal size. J Cereb Blood Flow Metab 19:218-229
212. Mozley PD, Kim HJ, Gur RC, Tatsch K, Muenz LR, McElgin WT, Kung MP, Mu M, Myers AM, Kung HF (1996) Iodine-123-IPT SPECT imaging of CNS dopamine transporters: nonlinear effects of normal aging on striatal uptake values. J Nucl Med 37:1965-1970
213. 18F-fallypride in nonhuman primates using positron emission tomography. Synapse 27:1-13
214. 123I]β-CIT SPECT visualizes dopamine transporter loss in de novo parkinsonian patients. Eur Neurol 39:44-48
215. 2 dopamine receptors in Parkinson's disease using SPECT and iodine-123-iodobenzamide. J Nucl Med 36:384-393
216. 123I]β-CIT single-photon emission tomography in DOPA-responsive dystonia. Mov Disord 12:448-451
217. 123I] beta-CIT. Mov Disord 13:319-323
218. Neumeyer JL, Wang S, Gao Y, Milius RA, Kula NS, Campbell A, Baldessarini RJ, Zea-Ponce Y, Baldwin RM, Innis RB (1994) N-Ω-Fluoroalkyl analogs of (1R)-2β-carbomethoxy-3β-(4-iodophenyl)-tropane (β-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. J Med Chem 37:1558-1561
219. Ng G, O'Dowd B, Lee S, Chung HT, Brann MR, Seeman P et al. (1996) Dopamine receptor dimers and receptor blocking peptides Biochem Biophys Res Commun 227:200-204
220. Nomura Y (1997) Segawa disease. Rinsho Shinkeigaku 37:1137-1138
221. 2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 33:227-235
222. 11C]N-methylspiperone. Psychiatry Res 61:67-83
223. 2 dopamine receptor density at different phases of the menstrual cycle. Psychiatry Res 83:1-6
224. 2 dopamine receptor occupancy and plasma antipsychotic drug levels in man. Int Clin Psychopharmacol 10:81-85
225. 2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. Psychopharmacology 119:345-348
226. 2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology 16:1-7
227. 123I-iodobenzamide binding. J Neural Transm 103:1093-1103
228. 1 receptors in schizophrenia revealed by PET. Nature 385:634-636
229. 123I-iodobenzamide and 2 betacarbomethoxy-3 beta-(4-iodophenyl) tropane single photon emission computed tomographic study. Arzneimittelforschung 47:692-699
230. Overweg J (1985) Withdrawal of antiepileptic drugs in seizure-free adult patients. Prediction of outcome. Thesis, University of Amsterdam, The Netherlands, pp 3-8
231. 2 receptors in progressive supranuclear palsy: an autoradigraphic study. Ann Neurol 32:703-707
232. 2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder. Arch Gen Psychiatry 52:471-477
233. 2 receptor binding in the basal ganglia. Psychol Med 24:423-429
234. Petroff OAC, Rothman DL, Behar KL, Mattson RH (1996) Human brain GABA levels rise after initiation of vigabatrin therapy but fail to rise further with increasing dose. Neurology 46:1459-1463
235. 2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 340:199-202
236. 123I IBZM SPET (single photon emission tomography) study. Psychol Med 23:791-797
237. 123I-IBZM single photon emission computerised tomography study. Br J Psychiatry 164:16-26
238. Pilowsky LS, Mulligan RS, Acton PD, Ell PJ, Costa DC, Kerwin RW (1997) Limbic selectivity of clozapine. Lancet 350:490-491
239. Pirker W, Brücke T, Riedl M, Clodi M, Luger A, Asenbaum S, Podreka I, Deecke L (1994) Iodine-123-IBZM-SPECT: studies in 15 patients with pituitary tumors. J Neural Transm [Gen Sect] 97:235-244
240. 2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT. J Nucl Med 37:1931-1937
241. Pirker W, Asenbaum S, Wenger S, Kornhuber J, Angelberger P, Deecke L, Podreka I, Brücke T (1997) Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease. J Nucl Med 38:1711-1717
242. 2 receptor binding characteristics in vivo. Am J Psychiatry 155:768-773
243. 2 receptor availability in healthy volunteers. Mol Psychiatry 3:256-260
244. Reith J, Benkelfat C, Sherwin A, Yasuhara Y, Kuwabara H, Andermann F et al. (1994) Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci USA 91:11651-11654
245. Remy P, de Recondo A, Defer G, Loc'h C, Amarenco P, Plante-Bordeneuve V, Dao-Castellana MH, Bendriem B, Crouzel C, Clanet M et al. (1995) Peduncular "rubral" tremor and dopaminergic denervation: a PET study. Neurology 45:472-477
246. Reynolds G P, Czudek C, Bzowej N, Seeman P (1987) Dopamine receptor asymmetry in schizophrenia. Lancet 329:979
247. Richens A (1992) New drugs for epilepsy: a rapidly changing scene. Acta Neurol Scand 86:65-70
248. Riederer P, Sofic E, Konradi C et al. (1989) The role of dopamine in the control of neurobiological functions. In: Flückiger E, Müller EE, Thorner MO (eds) The role of brain dopamine (Basic and clinical aspects of neuroscience, vol 3). Springer, Berlin, Germany, pp 1-17
249. Ring HA, Trimble MR, George MS, Costa DC, Verhoeff NP G, Ell PJ (1992) Effect of vigabatrin on striatal dopamine receptors: evidence in humans for interactions of GABA and dopamine systems. J Neurol Neurosurg Psychiatry 55:758-761
250. Rinne JO (1987) Muscarinic and dopaminergic receptors in the aging human brain. Brain Res 404:162-168
251. 11C]raclopride. J Cereb Blood Flow Metab 13:310-314
252. 2 receptor changes during the progression of early Parkinson's disease. Mov Disord 8:134-138
253. 11C]raclopride. J Neurol Sci 132:156-161
254. 11C]NNC 756. J Sleep Res 5:262-264
255. 11C]β-CFT is reduced in Alzheimer's disease assessed by positron emission tomography. Neurology 50:152-156
256. Ross E M (1990) Viral hijack of receptors. Nature 344:707-708
257. 3H-raclopride in the mouse brain in vivo. Arch Pharmacol 340:6-12
258. Rutgers AWF, Lakke JPWF, Paans AMJ et al. (1987) Tracing of dopamine receptors in hemiparkinsonism with positron emission tomography (PET). J Neurolog Sci 80:237-248
259. 18F]6-L-fluorodopa studies in two patients with putaminal implants. Ann Neurol 31:166-173
260. 123I]IPCIT as single-photon emission tomography radiotracers for the dopamine transporter in nonhuman primates. Eur J Nucl Med 22:4-11
261. 11C]raclopride at dopamine receptors in human subjects. Am J Psychiatry 154:1209-1213
262. Schlaug G, Hefter H, Engelbrecht V, Kuwert T, Arnold S, Stocklin G, Seitz RJ (1996) Neurological impairment and recovery in Wilson's disease: evidence from PET and MRI. J Neurol Sci 136:129-139
263. 11C-raclopride PET. Synapse 28:66-70
264. Schroder J, Silvestri S, Bubeck B, Karr M, Demisch S, Scherrer S, Geider FJ, Sauer H (1998) Biol Psychiatry 43:660-665
265. 123I-IBZM-SPECT. J Neurol Neurosurg Psychiatry 57:1047-1056
266. 123IBZM-SPECT in a Wilson's disease patient with general dystonia. Mov Disord 7:58-61
267. 123I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism. Neurology 43:S17-S20
268. 2-signal intensity in de novo Wilson's disease. Neurology 44:1079-1082
269. Schwarz J, Oertel WH, Tatsch K (1996) Iodine-123-iodobenzamide binding in parkinsonism: reduction by dopamine agonists but not L-dopa. J Nucl Med 37:1112-1115
270. 123I]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy. Mov Disord 12:898-902
271. 123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism. Mov Disord 13:16-19
272. Scillitani A, Dicembrino F, Di Faxio P, Vettori PP, D'Angelo V, Scarabino T, Liuzzi A (1995) In vivo visualization of pituitary dopaminergic receptors by iodine-123 methoxybenzamide (IBZM) correlates with sensitivity to dopamine agonists in two patients with macroprolactinomas. J Clin Endocrinol Metab 80:2523-2525
273. 1 receptor number - a sensitive PET marker for early brain degeneration in Huntington's disease. Eur Arch Psychiatr Clin Neurosci 243:249-255
274. Sedvall G, Pauli S, Karlsson P, Farde L, Nordstrom AL, Nyberg S, Halldin C (1995a) PET imaging of neuroreceptors in schizophrenia. Eur Neuropsychopharmacol 5:25-30
275. Sedvall G, Farde L, Hall H, Halldon C, Karlsson P, Nordstrom AL, Nyberg S, Pauli S (1995b) Utilization of radioligands in schizophrenia research. Clin Neurosci 3:112-121
276. Seeman P, Grigoriadis D (1987) Dopamine receptors in brain and periphery. Neurochem Int 10:1-25
277. 2 receptors, yet occupy high levels of these receptors. Mol Psychiatry 3:123-134
278. Seeman P, Bzowej N H, Guan H C et al. (1987) Human brain dopamine receptors in children and aging adults. Synapse 1:399-404
279. 3H]raclopride: implications for positron emission tomography of the human brain. Synapse 3:96-97
280. 2 receptor reveals different densities for dopamine receptor antagonist ligands - implications for human brain positron emission tomography. Eur J Pharmacol Mol Pharm 227:139-146
281. 4 receptors are elevated in schizophrenia. Nature 365:441-445
282. 3H]benzquinoline. Synapse 25:137-146
283. 123I]β-CIT striatal uptake correlates with symptom severity in idiopathic Parkinson's disease. Ann Neurol 38:589-598
284. Seibyl JP, Zea-Ponce Y, Brenner L, Baldwin RM, Krystal JH, Offord SJ, Mochoviak S, Charney DS, Hoffer PB, Innis RB (1996a) Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796. J Nucl Med 37:11-15
285. Seibyl J, Marek K, Sheff K, Innis R (1996b) [I-123]β-CIT brain SPECT imaging of dopamine transporters in Parkinson's disease and Parkinson syndrome. J Nucl Med 37:134P
286. Seibyl JP, Marek K, Sheff K, Baldwin RM, Zoghbi S, Zea-Ponce Y, Charney DS, van Dyck CH, Hoffer PB, Innis RB (1997) Test/retest reproducibility of iodine-123-βCIT SPECT brain measurement of dopamine transporters in Parkinson's patients. J Nucl Med 38:1453-1459
287. Seibyl JP, Marek K, Sheff K, Zoghbi S, Baldwin RM, Charney DS, van Dyck CH, Innis RB (1998) Iodine-123-β-CIT and iodine-123-β-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J Nucl Med 39:1500-1508
288. 2 receptor imaging in Parkinson's disease and striato-nigral degeneration by PET. J Nucl Med 33:917
289. Singer HS, Wong DF, Brown JE et al. (1992) Positron emission tomography evaluation of dopamine D-2 receptors in adults with Tourette syndrome. Adv Neurol 58:233-239
290. Smith AD, Bolam JP (1990) The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurosci 13:259-265
291. 11C]raclopride and PET in normal human subjects. Am J Psychiatry 154:490-496
292. 11C-raclopride in normal human subjects. Neuropsychopharmacology 18:18-25
293. Snyder SH (1990) The dopamine connection. Nature 347:121-122
294. Soares JC, Innis RB (1999) Neurochemical brain imaging investigations of schizophrenia. Biol Psychiatry 46:600-615
295. Speelman JD (1991) Parkinson's disease and stereotaxic neurosurgery. Thesis, University of Amsterdam, The Netherlands, pp 11-58
296. Spencer DD, Robbins RJ, Naftolin F et al. (1992) Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. N Engl J Med 327:1541-1548
297. Staedt J, Stoppe G, Kogler A, Munz DL, Hajak G, Staedt U, Riemann H, Ruther E (1994) Nightly myoclonus sundrome (NMS) and resless legs syndrome (RLS) - review and case report. Fortschr Neurol Psychiatr 62:88-93
298. 2 receptor occupancy in narcoleptic patients in the course of treatment. Biol Psychiatry 39:107-111
299. Stejskal L, Tomanek Z (1981) Postural laterality in torticollis and torsion dystonia. J Neurol Neurosurg Psychiatry 44:1029-1034
300. 1 dopamine receptors measured by positron emission tomography. Psychopharmacology 103:41-45
301. 1 dopamine receptor binding in mood disorders measured by positron emission tomography. Psychopharmacology 106:14-18
302. Sullivan AM, Opacka-Juffry J, Blunt SB (1998) Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotrophic factor against 6-hydroxydopamine in vivo. Eur J Neurosci 10:57-63
303. Surmeier DJ, Reiner A, Levine MS, Ariano MA (1993) Are neostriatal dopamine receptors colocalized. Trends Neurosci 16:299-305
304. Szymanski S, Singer H, Giuliano J, Yokoi F, Dogan S, Villemagne V, Chin B, Gjedde A, Wong DF (1997) Basal ganglia dopamine release in Tourette syndrome. J Nucl Med 38:12P
305. Tani Y, Ishihara T, Kanai T, Ohno T, Andersson J, Lilja A, Antoni G, Fasth KJ, Bjurling P, Westerberg G et al. (1995) Effects of 6R-L-erythro-5,6,7,8-tetrahydrobiopterin on the dopaminergic and cholinergic receptors as evaluated by positron emission tomography in the rhesus monkey. J Neural Transm [Gen Sect] 102:189-208
306. Tatsch K, Kerner M, Linke R, Schwarz PD, Mozley PD, Hahn K (1998) Combined analysis of the pre- and postsynaptic dopaminergic system for improved discrimination between idiopathic and non-idiopathic parkinsonian syndromes. J Nucl Med 39:124P
307. Tauscher J, Kufferle B, Asenbaum S, Brücke T, Kasper S (1997) Previous treatment as a confounding variable in studies with novel antipsychotics: two cases of high dopamine-2 receptor occupancy with quetiapine. Psychopharmacology 133:102-105
308. 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patents treated with olanzapine in comparison to clozapine and haloperidol. Psychopharmacology 141:175-181
309. 11C]raclopride displacement and PET. Neurology 46:1430-1436
310. 123I-epidepride in patients with schizophrenia and controls. J Psychiatr Neurosci 22:39-45
311. Tiihonen J, Kuikka J, Bergström K, Hakola P, Karhu J, Ryynänen OP, Fohr J (1995) Altered striatal dopamine re-uptake site densities in habitually violent and non-violent alcoholics. Nature Med 1:654-657
312. Tiihonen J, Kuikka JT, Bergström KA, Lepola U, Koponen H, Leinonen E (1997) Dopamine reuptake site densities in patients with social phobia. Am J Psychiatry 154:239-242
313. Tiihonen J, Vilkman H, Räsänen P, Ryynänen OP, Hakko H, Bergman J, Hämäläinen T, Laakso A, Haaparanta-Solin M, Solin O, Kuoppamäki M, Syvälahti E, Hietala J (1998) Striatal presynaptic dopamine function in type 1 alcoholics measured with positron emission tomography. Mol Psychiatry 4:156-161
314. Tikofsky RS, Ichise M, Seibyl JP, Verhoeff NPLG (1999) Functional brain SPECT imaging: 1999 and beyond. In: Freeman LM (ed) Nuclear medicine annual 1999. Lippincott Williams & Wilkins, New York, pp 193-263
315. 123I]β-CIT SPECT. J Neurol 245:14-20
316. Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, van Royen EA, Stoof JC, Wolters EC (1998b) Iodine-123-N-Ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease. J Nucl Med 39:1143-1148
317. Torres EM, Fricker RA, Hume SP, Myers R, packa-Juffry J, Ashworth S, Brooks DJ, Dunnett SB (1995) Assessment of striatal graft viability in the rat in vivo using a small diameter PET scanner. Neuroreport 6:2017-2021
318. Trugman JM, Geary WA II, Wooten GF (1986) Localization of D-2 dopamine receptors to intrinsic striatal neurones by quantitative autoradiography. Nature 323:267-269
319. 11C] DOPA disposition in the monkey brain. Brain Res 713:92-98
320. 2 receptor quantification and superior temporal gyrus: volume determination in 14 chronic schizophrenic subjects. Psychiatry Res 67:155-158
321. Turjanski N, Sawle GV, Playford ED, Weeks R, Lammertsma AA, Lees AJ, Brooks DJ (1994) PET studies of the presynaptic and postsynaptic dopaminergic system in Tourette's syndrome. J Neurol Neurosurg Psychiatry 57:688-692
322. 2 receptor binding in patients with Huntington's disease and other choreas. A PET study. Brain 118:689-696
323. 2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology 49:717-723
324. 11C-raclopride PET studies. Neurology 52:932-937
325. 123I]β-CIT SPECT. J Nucl Med 36:1175-1181
326. 123I-IBZM single photon emission computed tomography. Arch Neurol 50:513-516
327. Varrone A, Innis RB, Marek K, Zoghbi S, Balrdwin R, Seibyl JP (1998) Evaluation of patients with parkinsonism with [I-123]IBF and β-CIT SPECT. J Nucl Med 39:14P
328. Verhagen Metman L, Blanchet PJ, van den Munckhof P, Del Dotto P, Natte R, Chase TN (1998) A trial of dextromethorphan in parkinsonian patients with motor response complications. Mov Disord 13:414-417
329. Verhoeff NPLG (1998) Ligands for neuroreceptor imaging by single photon emission tomography (SPET) or positron emission tomography (PET). In: Murray IPC, Ell PJ (eds) Nuclear medicine in clinical diagnosis and treatment, 2nd edn. Churchill Livingstone, New York, pp 521-562
330. 2-receptor imaging with dynamic I-123 IBZM SPET in patients with schizophrenia or HIV encephalopathy. In: Schmidt HAE, Van der Schoot JB (eds) The state of the art of nuclear medicine in Europe. European Nuclear Medicine Congress, Amsterdam, May 20-24, 1990 (Nucl Med, Suppl 17) Schattauer, Stuttgart-New York, pp 207-212
331. 2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with a TSH/PRL-producing pituitary macroadenoma. Eur J Nucl Med 20:555-561
332. 123I-iodobenzamide SPECT in patients with parkinsonian syndromes. In: De Deyn PP, Dierckx RA, Alavi A, Pickut BA (eds) A Textbook of SPECT in Neurology and Psychiatry. Libbey, London, pp 167-179
333. Verhoeff NPLG, Booij J, Innis RB, Van Royen EA (1997b) Neuroreceptor ligand imaging by SPECT in parkinsonian syndromes. In: De Deyn PP, Dierckx RA, Alavi A, Pickut BA (eds) A Textbook of SPECT in Neurology and Psychiatry. Libbey, London, pp 149-165
334. 123I]iomazenil SPECT and GABA MRS. Epilepsia 40:1433-1438
335. 123I]IBZM as measured with SPECT in MPTP monkeys. Synapse 17:115-124
336. 123I]β-CIT binding with SPECT in controls, early and late Parkinson's disease. Nucl Med Biol 22:985-991
337. 11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations. J Neurosci 18:419-427
338. 11C]WIN35,428 PET scans. Synapse 32:44-50
339. Volkow ND, Fowler JS, Wolf AP, Hitzemann R, Dewey S, Bendriem B, Alpert R, Hoff A (1991) Changes in brain glucose metabolism in cocaine dependence and withdrawal. Am J Psychiatry 148:621-626
340. 2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 14:169-177
341. Volkow ND, Fowler JS, Gatley J, Logan J, Wang GJ, Ding YS, Dewey S (1996a) PET evaluation of the dopamine system of the human brain. J Nucl Med 37:1242-1256
342. 18F-N-methylspiroperidol. Psychiatry Res 67:11-16
343. Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley SJ, Hitzemann R, Smith G, Fields SD, Gur R (1996c) Dopamine transporters decrease with age. J Nucl Med 37:554-559
344. Volkow ND, Wang GJ, Fowler JS, Logan J, Ding YS, Gatley J, Hitzemann R, Pappas N (1996d) Decreases in dopamine receptors but not in dopamine transporters in alcoholics. J Nucl Med 37:33P
345. Volkow ND, Wang GJ, Fischman MW, Foltin RW, Fowler JS, Abumrad NN, Vitkun S, Logan J, Gatley SJ, Pappas N, Hitzemann R, Shea CE (1997a) Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 386:827-830
346. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Hitzemann R, Chen AD, Dewey SL, Pappas N (1997b) Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 386:830-833
347. Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, Hitzemann R, Pappas N (1998) Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenydate. Am J Psychiatry 155:1325-1331
348. Volkow ND, Wang GJ, Fowler JS, Hitzemann R, Angrist B, Gatley SJ, Logan J, Ding YS, Pappas N (1999a) Association of methylphenidate-induced craving with changes in right striato-orbitofrontal metabolism in cocaine abusers: implications in addiction. Am J Psychiatry 156:19-26
349. Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, Dewey SL, Hitzemann R, Gifford AN, Pappas NR (1999b) Blockade of striatal dopamine transporters by intravenous methylphenidate is not sufficient to induce self-reports of "high". J Pharmacol Exp Ther 288:14-20
350. Wang GJ, Volkow ND, Fowler JS, Fischman M, Foltin R, Abumrad NN, Logan J, Pappas NR (1997) Cocaine abusers do not show loss of dopamine transporters with age. Life Sci 61:1059-1065
351. 1 receptors in human brain: a PET study. Synapse 30:56-61
352. Weinberger DR (1987) Implications of notmal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44:660-669
353. Weinberger DR, Lipska BK (1995) Cortical maldevelopment, anipsychotic drugs, and schizophrenia: a search for common ground. Schizophr Res 16:87-110
354. Weinberger DR, Berman KF, Suddath R, Fuller Torrey E (1992) Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins. Am J Psychiatry 149:890-897
355. Welz A, Pogarell O, Tatsch K, Schwarz J, Cryssagis K, Reichart B (1997) Surgery of the thoracic aorta using deep hypothermic total circulatory arrest. Are there neurological consequences othe rthan frank cerebral defects? Eur J Cardiothorac Surg 11:650-656
356. 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease. Mov Disord 13:438-445
357. Wichmann T, Vitek J, DeLong MR (1995) Parkinson's disease and the basal ganglia: lessons from the laboratory and from neurosurgery. Neuroscientist 1:236-244
358. Widner H, Tetrud J, Rehncrona S et al. (1992) Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N Engl J Med 327:1556-1563
359. 1 receptors in prefrontal cortex. Nature 376:572-575
360. Willner P, Muscat R, Papp M, Sampson D (1991) Dopamine, depression and anti-depressant drugs. In: Willner P, Scheel-Krüger (eds) The mesolimbic dopamine system: from motivation to action. Wiley, London, pp 388-410
361. 2 receptor binding. Science 273:1225-1227
362. Wolkin A, Barouche F, Wolf A P et al. (1989a) Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 146:905-908
363. Wolkin A, Brodie JD, Barouche F et al. (1989b) Dopamine receptor occupancy and plasma haloperidol levels. Arch Gen Psychiatry 46:482-483
364. Wong DF, Singer H, Marenco S, Brown J, Yung B, Yokoi F, Chan B, Mathews W, Musachio J, Dannals RF (1994) Dopamine transporter reuptake sites measured by [C11]WIN 35,428 PET imaging are elevated in Tourette syndrome patients. J Nucl Med 35:130P
365. 2-like dopamine rceptors: theory, validation, and changes during normal aging. J Cereb Blood Flow Metab 17:316-330
366. 2 dopamine receptor density in Tourette syndrome measured by PET. J Nucl Med 38:1243-1247
367. D in schizophrenia by PET. J Nucl Med 38:11P (Abstract)
368. 3H]raclopride binding on the rat brain. Synapse 9:188-194
369. 2 densities and the schizophrenic brain. Schizophr Res 32:201-206
370. Zelnik N, Angel I, Paul SM, Kleinman JE (1986) Decreased density of human striatal dopamine uptake sites with age. Eur J Pharmacol 126:175-176